EVATRAN (The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients): study protocol for a cross-over randomized controlled trial.

Date publication

novembre 2025

Journal

Trials

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Simon A, Girerd N, Jaisser F, Bozec E, Lepage X, Mercklé L, Rossignol P, Frimat L, Girerd S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41204172

Résumé

Arterial stiffness is a major prognostic factor of cardiovascular (CV) morbi-mortality in kidney transplant (KT) patients. Preclinical studies have demonstrated that the vascular toxicity of calcineurin inhibitors (CNI) is mediated through the activation of the mineralocorticoid receptor (MR) in vascular smooth muscle cells. Additionally, the role of MR in contributing to arterial stiffness is well documented in non-transplanted individuals. This study aims to investigate the impact of MR antagonist treatment on the progression of arterial stiffness in KT patients on cyclosporine.

Mots clés

Arterial stiffness, Calcineurin inhibitor, Cardiovascular, Cyclosporine, Eplerenone, Kidney transplant, Mineralocorticoid antagonist, Pulse wave velocity

Référence

Trials. 2025 11 7;26(1):479